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Abstract : Hepatitis C virus?HCV?infection can cause chronic liver disease; it has 
also been associated with lymphoproliferative disorders?LPDs?, such as cryoglobu-
linemia and B-cell non-Hodgkin?s lymphoma.  Our previous studies suggested that 
cryoglobulinemia, high titer of rheumatoid factor?RF?, and hypocomplementemia 
are immunological markers of LPDs.  In addition, recent therapies with direct-acting 
antivirals?DAAs?have achieved high rates of sustained virological response?SVR?
in patients with chronic hepatitis C?CH-C?.  This study analyzed the efficacy of 
DAA therapy in CH-C patients with cryoglobulinemia, and the association of bio-
chemical and other immune markers for LPDs with persistence of cryoglobulinemia 
in patients after DAA therapy.  Of 226 patients tested, 31?13.7??had cryoglobu-
linemia prior to receiving DAAs, and these individuals showed lower complement 4 
levels, decreased complement hemolytic activity, and higher IgM than patients without 
cryoglobulinemia.  Of the 24 cryoglobulinemia-positive patients?83??who could be 
followed for 24 weeks, 20 became cryoglobulinemia negative after the therapy.  The 
remaining four patients retained the abnormal LPD markers, indicating the possibility 
of long-term LPD persistence even following successful eradication of HCV in CH-C 
patients.  Thus, long-term follow-up is recommended to avoid exacerbation of extra-
hepatic manifestations as well as new events.
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Introduction
?Hepatitis C virus?HCV?infects 71 million people worldwide, causing chronic hepatitis
?CH?, liver cirrhosis?LC?, and eventually hepatocellular carcinoma1?2?.  Chronic HCV infection 
causes considerable morbidity and mortality worldwide due to the high percentage of patients 
progressing to cirrhosis and end-stage liver disease3?4?.  Recent studies show that treatment with 
direct-acting antivirals?DAAs?achieves higher rates of sustained virological response?SVR?in 
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CH-C patients than interferon?IFN?-based therapies5-8?.
?HCV infection is also associated with extrahepatic manifestations in some patients, including 
mixed cryoglobulinemia9-11?and B-cell non-Hodgkin?s lymphoma?NHL?12?.  Our group 
previously reported a high prevalence of abnormal markers for lymphoproliferative disorders
?LPDs?in patients with CH-C13?, and in particular, an association with HCV infection and / or 
B cell adsorption.  Cryoglobulinemia, high levels of rheumatoid factor?RF?, low complement 
levels, and clonal expansion of B cells were also frequently observed in the patients with 
CH-C; approximately 74? showed RNA positivity for HCV in B cells isolated from those 
patients.  These results suggested that HCV infection is important in the manifestation of both 
liver disease and immunological disorders in affected patients.  Indeed, a recent study also 
demonstrated abnormal activation of B cells in association with both CH-C and chronic infection 
with hepatitis B?CH-B?14?.  
?The extrahepatic manifestations of hepatitis viral infections have been associated with the presence 
of immune complexes comprising HCV virions and / or viral protein, immunoglobulin?IgM with 
rheumatoid factor?RF?activity?, and complement proteins15?.  Indeed, antibodies to HCV?anti-
HCV?and HCV RNA are detected more frequently in patients with non-Hodgkin?s lymphoma than 
in the general population?30? vs. 1.3??12?, while cryoglobulinemia represents the oligoclonal 
proliferation of B cells and occurs in 19-56? of patients infected with HCV11?16-18?.  HCV 
has also been implicated in relapsed cryoglobulinemia after treatment with DAAs in short-
term follow-ups19?.  Based on these observations, cryoglobulinemia is considered a strong LPD 
marker.  In addition, rheumatoid factor?RF?in high titers and hypocomplementemia?low 
levels of C3, C4, or CH50?are regarded as immunological markers for autoimmune disease and 
lymphoproliferation, such as in Sjögren?s syndrome20?.  
?In the last 5 years, antiviral therapies against CH-C have advanced remarkably from IFN-
based therapies to DAAs, with improved SVR ratios.  In terms of mechanisms, IFN therapies 
enhance the host defense responses in patients by stimulating the immune system, whereas 
DAAs directly target viral proteins needed for viral replication, processing, and assembly.  Thus, 
we can analyze the direct effects of viral eradication after DAAs and associated changes in 
extrahepatic manifestations without over-stimulation of the immune system that occurs with IFN 
treatment.  In this study, we investigated the prevalence of abnormal LPD markers, such as 
cryoglobulinemia in CH-C patients before and during DAAs administration.
Patients and methods
Study subjects
?A total of 226 Japanese patients?CH-C, n?165; LC, n?61?admitted to Showa University 
Hospital and Showa University Koto Toyosu Hospital were enrolled in this study.  The 159 
patients infected with HCV genotype 1, were treated with SOF / LDV?n?86?, DCV / ASV
?n?48?, OBV / PTV / r?n?9?, EBR?GZR?n?9?, and GCR / PBV?n?7?, respectively, 
and the 67 patients infected with HCV genotype 2 were treated with SOF?RBV?n?57?
and GCR / PBV?n?10?.  Table 1 details the profiles of DAAs used in this study.  Briefly, 
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NS3 is a protease inhibitor, while NS5B is the polymerase inhibitor of HCV, and NS5A is 
the nonstructural protein 5A, which plays a key role in viral replication and virion assembly. 
Ritonavir is one of the anti-HIV protease inhibitors which inactivates cytochrome P450 3A4
?CYP3A4?and boosts HCV NS3 inhibitors21?.  
?SVR was defined as undetectable HCV RNA levels 24 weeks after the end of the 
treatment.  Viral information?genotype of HCV and titer of HCV RNA in serum?, host 
factors?age, gender, platelet counts, serum levels of alanine transaminase?ALT?, immunological 
markers?IgG, IgA, and IgM?and markers for LPD?cryoglobulinemia, high levels of RF, 
hypocomplementemia??were analyzed.  All variables including HCV-RNA level were evaluated 
before treatment, 1 and 8 weeks after the start of treatment, at the end of treatment, and 8 
and 24 weeks after the end of treatment.  Clinical characteristics of the CH-C patients are 
shown in Table 1.  This was a retrospective observational study of patients with chronic HCV 
infection who received different DAAs therapies and who achieved SVR between February 2012 
and November 2018.  Each participant provided written informed consent, and this study was 
approved by the ethics committees of Showa University Hospital?approval number: 660?and 
Showa University Koto Toyosu Hospital?approval number: 14H007?, both of which are suitably 
constituted according to the 1975 Declaration of Helsinki.
Markers of lymphoproliferative disorders
?Semi-quantitative centrifugation was used to detect cryoglobulinemia, wherein blood samples 
were centrifuged at 600 ? g for 20 min at 37?.  The serum was then cooled to 4? and 
allowed to stand for 48 hours, and then centrifuged again at 2,500 ? g for 10 min at 4?. 
The appearance of cryocrit at 4? and its disappearance after warming to 37? for 20 min 
was positive for cryoglobulins, while appearance of a small amount of cryocrit at 4? and 
disappearance of cryocrit after warming at 37? for 20 min was judged as weakly positive for 
cryoglobulins: no cryocrit at 4? was considered negative for cryoglobulins.  RF was measured 
by latex nephelometry, and C3, C4 or CH50 activities were measured by nephelometry or 
Mayer?s method, respectively.
Table 1.  Profile of direct-acting antivirals used in this study
HCV 
Genotype
DAAs
Number 
of cases
NS3 
inhibitor
NS5A 
inhibitor
NS5B 
inhibitor
Booster of 
NS3 inhibitor
other 
antiviral
1
DCV?ASV 48 asunaprevir daclatasvir
LDV?SOF 86 ledipasvir sofosbuvir
OBV?PTV/r ?9 paritaprevir ombitasvir ritonavir?
EBR?GZR ?9 grazoprevir elbasvir
GCR/PBV ?7 glecaprevir pibrentasvir
2
SOF?RBV 57 sofosbuvir ribavirin
GCR / PBV 10 glecaprevir pibrentasvir
?Ritonavir inactivates CYP3A4
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Statistical analysis
?Median values of continuous variables without normal distribution were compared using the 
Mann-Whitney U test.  Discontinuous variables were compared using the chi-square test or 
Fisher?s exact test.  P values? 0.05 were judged to be statistically significant.  The values of the 
normal distribution were expressed as mean ? standard deviation?SD?.  JMP Pro 14 software
?SAS Institute, Cary, NC?was used for statistical revision.
Results
Abnormality of LPD markers in CH-C patients
?Table 2 shows the clinical characteristics of HCV-infected patients.  Cryoglobulinemia was 
identified in 13.7? of CH-C patients who enrolled in this study, and this prevalence was lower 
than that previously reported?24??22?.  A high prevalence of hypocomplementemia?low C3
?33.6??, low C4?10.6??, low CH50?59.3???, and high levels of RF?37.6??were detected 
in the patients before DAAs administration, and interestingly, these findings were identical to the 
previous report.
Host and viral markers associated with cryoglobulinemia in CH-C patients
?Among the 226 patients with CH-C, 31 cases?13.7??were positive for Cg.  We next 
analyzed the associated markers for cryoglobulinemia in this cohort.  Table 3 indicated that 
no viral marker was identified, while a lower level of albumin and higher level of AFP were 
correlated with a Cg-positive status.  Among the LPD markers, higher IgM, low C4, and low 
CH50 were associated with Cg positivity in CH-C patients.
Table 2.  Clinical characteristics of HCV-infected patients?n?226?
Age?years; median? 67?24-88?
Gender?Male / Female? 104?50.4??/ 122?29.6??
Outcome of DAAs therapy?SVR / non SVR? 220?97.3??/ ??6??2.7??
HCV RNA?log IU/ml? ?5.9 ? 0.1
HCV Genotype?1 / 2? 159?70.4??/ ?67?29.6??
CH / LC 165?73.0??/ ?61?26.9??
ALT?IU/l? 54.1 ? 3.1
Platelets??104/mm3? 16.4 ? 0.4
Albumin?g/dl? ?4.1 ? 0.4
FIB4 index ?3.6 ? 0.2
AFP?ng/ml? ?9.9 ? 1.1
Cryoglobulinemia 31 / 226?13.7??
IgG?mg/dl? 1,810 ? 34
IgA?mg/dl? 252 ? 11
IgM?mg/dl? 120 ? 4.9
C3??86 mg/dl? 76 / 226?33.6??
C4??10 mg/dl? 24 / 226?10.6??
CH50??20 U/ml? 134 / 226?59.3??
Rheumatoid factor?? 15 IU/ml? 85 / 226?37.6??
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The changing status of cryoglobulinemia after treatment with DAAs
?We next analyzed the cryoglobulinemia response in patients treated with DAAs.  Circulating 
Cgs are thought to comprise HCV and / or viral protein, IgM with RF activity, and complements, 
and thus eradicating the HCV component might lead to Cg destruction15?.  Among the 24 
patients observed for the full 24 weeks after DAA treatment, 20?83??became Cg-negative. 
Further follow-up of more than 6 months after the end of treatment showed that the remnant 
circulating Cgs disappeared in two more patients?Fig. 1?.  These results suggest that clearing 
the Cg complex completely could take a long time, possibly more than 1 year after the end of 
treatment.
Status of the other LPD markers in patients not cleared of cryoglobulinemia
?Tables 4 and 5 describe the clinical characteristics and LPD markers both before and after 
DAA therapy in patients who retained some level of cryoglobulinemia.  Nine patients were still 
Cg-positive at 8 weeks after therapy?Table 4?, and four remained positive at 24 weeks after 
therapy?Table 5?.  Table 4 showed that low CH50?CH50? 20 U/ml?was measured in 8 of 9 
patients before therapy, and 6 of the 8 patients?75??retained the low-CH50 status.  High RF
?RF?15 IU/ml?levels were observed in 6 of 9 patients before therapy, and that status remained 
unchanged in these patients.  High IgG?IgG?1,800 mg/dl?and high IgM?IgM?200 mg/dl?
were retained in 3 of 5 patients?60??and 2 of 4 patients?50??, respectively, at 24 weeks 
after therapy.  All the patients showed improved ALT and AFP.  The FIB4 index, which was 
associated with hepatic fibrosis?F3-F4?3.25?, was improved in all but one patient?No. 4?. 
These results indicate that liver injury and markers of HCC and fibrosis were improved at 8 
Table 3.  Univariable analysis for Cg???status in 220 CH-C patients  
Cg positive?n?31? Cg negative?n?189? P-value
Age?years; median? 69?24-83? 67?33-88? N.S.
Gender?Male / Female? 10?32.3??/ 21?67.7?? 93?49.2??/ 96?50.8?? N.S.
HCV RNA?log IU/ml? 5.8 ? 0.2 5.9 ? 0.1 N.S.
HCV Genotype?1 / 2? 21?67.7??/ 10?22.3?? 135?71.4??/ 54?28.6?? N.S.
CH / LC 22?73.3??/ ?8?26.7?? 140?79.1??/ 37?20.9?? N.S.
ALT?IU/l? 50.8 ? 8.4 55.2 ? 3.4 N.S.
Platelets??104 /mm3? 16.5 ? 1.1 16.4 ? 0.4 N.S.
Albumin?g/dl? 3.9 ? 0.1 4.1 ? 0.0 0.032
FIB4 index 3.9 ? 0.5 3.6 ? 0.2 N.S.
AFP?ng/ml? 16.9 ? 3.0 8.9 ? 1.2 0.0137
IgG?mg/dl? 1,908 ? 90 1,809 ? 36 N.S.
IgA?mg/dl? 240 ? 30 254 ? 28 N.S.
IgM?mg/dl? 149 ? 13 116 ? 5.4 0.0194
C3??86 mg/dl? 12 / 31?38.7?? ?64 / 189?33.9?? N.S.
C4??10 mg/dl? ?8 / 31?25.8?? ?16 / 189??8.5?? 0.0041
CH50??20 U/ml? 26 / 31?83.9?? 108 / 189?57.1?? 0.0047
RF?? 15 IU/ml? 13 / 31?41.9?? ?71 / 189?37.6?? N.S.
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weeks after the end of DAA therapy, while the abnormal LPD markers persisted.
?At 24 weeks after the end of DAA therapy, 3 of the 4 patients who remained Cg-positive 
also retained abnormal LPD markers, indicating that several immune disorders persisted even 
after 24 weeks in the CH-C patients who showed no evidence of HCV?Table 5?.  
Discussion
?It has been proven epidemiologically that HCV causes a variety of extrahepatic manifestations, 
including cardiovascular diseases and dysfunction of the central nervous system15?.  In these 
manifestations, LPDs are most closely associated with HCV infection22-24?.  Zignego et al 25? 
reported the t?14; 18?translocation and overexpression of bcl-2 in lymphoid cells of patients 
with a lymphoproliferative disorder associated with HCV infection.  It has been proposed that 
binding of HCV E2 protein to CD 81 and / or infection of B cells with HCV promotes B-cell 
clonality26?, and after the discovery of HCV, it was recognized that the majority of patients with 
mixed cryoglobulinemia were also infected with HCV9-11?.  Subsequent studies confirmed that 
up to 90? of patients with mixed cryoglobulinemia have chronic HCV infection9?27-30?, although 
while circulating Cgs were present in 40-60? of HCV-infected patients, only 5-10? of these 
patients were symptomatic31?.  There is also substantial data indicating that HCV infects B cells 
and replicates13?32?, but it is not completely clear whether HCV infection with B cells is required 
to develop mixed cryoglobulinemia.  
?The strongest support for the relationship between HCV infection and cryoglobulinemia is the 
response to antiviral therapies.  Eradication of interferon therapy was reported to be effective 
partly for remission of cryoglobulinemia vasculitis on treatment, but some patients still relapsed 
Fig.?1.??Changing cryoglobulinemia status during and after the therapy with DAAs in 
CH-C patients. Cryoglobulin?Cg?status in 24 patients who were Cg positive 
before the DAA therapy is distinguished by colored boxes. Cg positive is 
portrayed as a black box, weakly positive as a dark gray box, and negative 
as a light gray box.
259Cryoglobulinemia in CH-C Patients after Therapy
after the end of the therapy33?.  Antiviral therapy using DAAs enables a high rate of SVR 
in CH-C patients, thus promising potential complete remission for HCV-related LPDs such as 
cryoglobulinemia.
?In this study, 31 of 220 CH-C patients?17.3??being Cg-positive presented a slightly lower 
prevalence than that reported previously13?, while the prevalence of other LPD markers was 
almost identical as in previous study groups.  In the 24 Cg-positive patients who were observed 
for 24 weeks after DAAs treatment, 83? of them became negative, indicating that eradication 
of HCV improved immunological abnormalities including HCV infection-related cryoglobulinemia. 
Nevertheless, Figure 1 indicates that some patients?8.3??retained cryoglobulinemia even 
after more than 6 months.  Our proposed model for developing cryoglobulinemia in CH-C 
patients is as follows15?.  At the first step, HCV viral particles and / or viral core protein bind 
to the B cells, leading to stimulation of B-cell activators.  These stimulated B cells are then 
clonally proliferated, and they could release the IgM with RF activity.  The IgM-RF molecules 
could form a cold precipitate of immune complexes comprising HCV particles and the C1q 
protein.  The HCV immune complexes then can bind to vascular endothelial cells, stimulate 
Table 4.  Clinical characteristics of patients who remained positive for cryoglobulinemia at 8 weeks after the end of therapy
No.
Gender
?F / M?
Age
?y? CH / LC
HCV 
RNA
?IU/ml?
Genotype
ALT
?Pre? ALT
T-Bil
?Pre? T-Bil
Alb
?Pre? Alb
AFP
?Pre? AFP
1 F 81 CH 6.1 1 ?43 12 0.7 0.7 3.5 4 20.6 7.5
2 M 69 CH 6.3 1 ?78 23 1.6 1.0 4.1 4.2 ?7.2 5.1
3 F 79 CH 7.2 1 ?18 11 0.6 0.4 4 4.2 ?3 4
4 F 78 CH 5.8 1 ?27 20 0.4 0.5 4 4.2 ?1.5 1.2
5 M 77 LC 5.6 1 ?28 26 2.4 1.1 2.9 2.9 ?6.4 5.5
6 F 67 CH 5.3 2 ?14 ?6 0.4 0.3 4.3 4.1 ?3     -
7 F 77 CH 4.8 2 ?27 15 0.7 0.8 4.2 4.3 ?3.8 3.6
8 M 56 CH 5.3 2 153 21 0.9 0.9 4.6 4.8 ?6.2 4.8
9 M 68 LC 4.5 2 ?86 31 1.2 0.5 3.2 4.1 32.7 10.4
No.
IgG
?Pre? IgG
IgM
?Pre? IgM
C3
?Pre? C3
C4
?Pre? C4
CH50
?Pre? CH50
RF
?Pre? RF
FIB-4
index
?Pre?
FIB-4 
index
1 1,875 1,449 169 ?81 ?71 ?74 ?9.3 11.6 ?5 29 ??  72 ?? 34 6.2 4.2
2 1,736 1,518 293 197 ?87 ?82 13.7 13.8 26 26 1,352 ? 473 5.6 4.1
3 1,433 1,422 490 417 ?74.9 109 ?2 ?2.8 ?6 15 1,244 1,071 2.6 2.8
4 ?2,681? 2,257 173 133 120 101 25.2 23.2 ?5 10 ??  54 ?? 48 3.2 3.5
5 2,827 2,305 ?92 ?49 ?49 ?52 ?3.8 ?5.6 ?5 ?5 ??  13 ?? 10 5.2 4
6 1,780 1,593 141 117 158 141 16.1 16.3 ?5 ?5 ?   194 ? 146 1.1 1.1
7 1,185 1,067 251 193 ?78 ?70 16.8 16.3 ?5 ?5 ??  43 ?? 29 2.4 2.5
8 2,367 1,563 105 ?84 121 ?96 18.7 16 ?5 ?5 ??  18 ?? 12 1.7 1.2
9 1,918 2,014 224 217 ?85 112 13.2 14.6 ?5 28 ??  15 ?? 16 3.4 2.3
?Dark box indicates that the abnormal LPD markers status was not cured.
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the complement system to produce vasoactive peptides, and recruit neutrophils to cause 
leukocytoclastic vasculitis.  Indeed, our results showed that cryoglobulinemia could persist even in 
SVR patients lacking serum HCV virions.  Also, those patients who were Cg-positive before the 
DAA therapy showed a higher prevalence of immunological abnormalities?hypocomplementemia, 
high IgM?and hepatic fibrosis?low albumin and high FIB-4 index?, than the Cg-negative 
patients.  In a few cases still showing cryoglobulinemia at 24 weeks after the DAAs treatment, 
some immunologic abnormalities also remained.  Together, the present data indicate that the 
immunological abnormalities accompanying cryoglobulinemia could persist for a long period after 
HCV eradication.  The B cells in such patients also could potentially incur somatic mutations, 
such as the t?14; 18?translocation and overexpression of bcl-2 described above, as well as overt 
malignant lymphoma.  Long-term observation is therefore recommended to monitor relapse or 
new onset of lymphoproliferative disease in CH-C patients.  
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